Urinary neopterin in patients with metastatic colon cancer treated with patupilone

Pteridines

Volumn 22, Issue 3, 2011, Pages 61-65

  Melichar, Bohuslav ^a,b   Kalábová, Hana ^b   Krcmová, Lenka ^b   Kasparová, Marketa ^b   Plísek, Jirí ^b   Cerman, Jaroslav ^b   Holecková, Petra ^b   Solichová, Dagmar ^b  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Colon cancer; Neopterin; Patupilone

Indexed keywords

CREATININE; EPOTHILONE B; NEOPTERIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTINUOUS INFUSION; CREATININE URINE LEVEL; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MALE; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; URINE LEVEL;

EID: 80155209766     PISSN: 09334807     EISSN: 21954720     Source Type: Journal    
DOI: 10.1515/pteridines.2011.22.1.61     Document Type: Article

References (15)

1. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-1214.
2. Jonker DJ, O Callaghan CJ, Karapetis C, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-2048.
3. Hurwitz H, Febrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
4. Larkin JMG, Kaye SB. Potential clinical applications of epothilones: a review of phase II studies. Ann Oncol 2007;18:v28-v34.
5. Pusztai L, Mendoza TR, Reuben JM, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004;25:94-102.
6. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 2002;87:21-27.
7. Melichar B, Urbanek L, Krcmova L, et al. Urinary neopterin, hemoglobin and peripheral blood cell counts in breast carcinoma patients treated with dose-dense chemotherapy. Anticancer Res 2008;28:2389-2396.
8. Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER. Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem 1989;27:81-141.
9. Melichar B, Solichova D, Melicharova K, Malirova E, Cermanova M, Zadak Z. Urinary neopterin in patients with advanced colorectal carcinoma. Int J Biol Markers 2006;21:190-198.
10. Melichar B, Solichová D, Freedman RS. Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. Int J Gynecol Cancer 2006;16:240-252.
11. Reibnegger G, Fuchs D, Fuith LC, et al. Neopterin as a marker for activated cell-mediated immunity: application in malignant disease. Cancer Detect Prev 1991;15:483-490.
12. Melichar B, Solichova D, Melicharova K, Cermanova M, Urminska H, Ryska A. Systemic immune activation, anemia and thrombocytosis in breast cancer patients treated by doxorubicin and paclitaxel. Pteridines 2006;17:107-114.
13. Bogdan C, Ding A. Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alfa and interleukin-1 in macrophages. J Leukocyte Biol 1992;52:119-121.
14. Allen JN, Moore SA, Wewers MD. Taxol enhances but does not induce interleukin-1beta and tumor necrosis factor-alpha production. J Lab Clin Med 1993;122:374-381.
15. Mullins DW, Burger CJ, Elgert KD. Paclitaxel enhances macrophage IL-12 production in tumorbearing hosts through nitric oxide. J Immunol 1999;162:6811-6818.